FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174236351> ?p ?o ?g. }

• W3174236351 abstract "Introduction. Despite favourable outcomes with chemoimmunotherapy for the majority of patients with diffuse large B-cell lymphoma (DLBCL), approximately one-third of patients experience relapsed or refractory disease portending poor prognosis. Patients ineligible for treatment intensification with salvage chemotherapy may be offered palliative chemotherapy or radiotherapy, and in the setting of single-site progression, salvage radiotherapy with curative intent. There remains a paucity of evidence for the latter with no randomised clinical trials or large series reported in the literature. The study was conducted to assess the outcomes of patients treated with salvage radiotherapy for limited stage relapsed / refractory DLBCL (rrDLBCL) at Monash Health, Australia, to determine its utility and inform future treatment algorithms. Methods. DLBCL cases (867 patients) diagnosed per WHO criteria at Monash Health, Melbourne, Australia, between 1996 - 2019 within the Haematology Database were analysed. Adult patients with rrDLBCL (including transformed indolent lymphoma) treated with salvage radiotherapy alone with curative intent were included in the study. Patients with inadequate clinical information or follow up data available or those in whom radiotherapy was administered as consolidation or clearly palliative intent were excluded. Results. From January 1996 - December 2019, 18 eligible patients were identified for inclusion in the study (12 refractory and 6 relapsed). A further 14 patients were excluded due to radiotherapy for clearly palliative intent (n = 7), CNS relapse (n = 5), consolidation (n = 1) or prior indolent lymphoma (n = 1). Median age at radiotherapy commencement for the study population was 71 years (range 42-83). 11/18 had biopsy-proven refractory disease, a further 3/18 had inconclusive biopsy with high suspicion of active disease on imaging and remaining patients were treated on basis of high clinical suspicion from PET imaging with sites not amenable to biopsy. Median radiotherapy dose was 42 Gy (range 10-50). After a median follow up of 14 months (range 1-64), 11/18 patients progressed (Fig. 1) after a median of 2 months (range 0-20). 7/18 (39%) patients remain in an ongoing remission without any progression events after a median of 29 months (range 13-64). Of the primary refractory subset, 4/12 (33%) remain free from progression with a median follow up of 32 months (range 13-64). Conclusion. Salvage radiotherapy with curative intent confers meaningful disease control for a subset of patients with limited stage rrDLBCL. Despite the small sample size and retrospective nature of the study, we conclude salvage radiotherapy should be considered a treatment option for patients ineligible for salvage chemotherapy in cases of single site rrDLBCL. These findings warrant further clinical investigation. Keywords: Radiation Therapy No conflicts of interests pertinent to the abstract." @default.
• W3174236351 created "2021-07-05" @default.
• W3174236351 creator A5013837790 @default.
• W3174236351 creator A5034869949 @default.
• W3174236351 creator A5057423528 @default.
• W3174236351 creator A5073055404 @default.
• W3174236351 creator A5079557357 @default.
• W3174236351 creator A5090258495 @default.
• W3174236351 date "2021-06-01" @default.
• W3174236351 modified "2023-09-25" @default.
• W3174236351 title "SALVAGE RADIOTHERAPY ASSOCIATES WITH DURABLE RESPONSE FOR A SUBSET OF PATIENTS WITH LIMITED STAGE REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA" @default.
• W3174236351 doi "https://doi.org/10.1002/hon.39_2881" @default.
• W3174236351 hasPublicationYear "2021" @default.
• W3174236351 type Work @default.
• W3174236351 sameAs 3174236351 @default.
• W3174236351 citedByCount "0" @default.
• W3174236351 crossrefType "journal-article" @default.
• W3174236351 hasAuthorship W3174236351A5013837790 @default.
• W3174236351 hasAuthorship W3174236351A5034869949 @default.
• W3174236351 hasAuthorship W3174236351A5057423528 @default.
• W3174236351 hasAuthorship W3174236351A5073055404 @default.
• W3174236351 hasAuthorship W3174236351A5079557357 @default.
• W3174236351 hasAuthorship W3174236351A5090258495 @default.
• W3174236351 hasBestOaLocation W31742363511 @default.
• W3174236351 hasConcept C121332964 @default.
• W3174236351 hasConcept C126322002 @default.
• W3174236351 hasConcept C141071460 @default.
• W3174236351 hasConcept C142424586 @default.
• W3174236351 hasConcept C143998085 @default.
• W3174236351 hasConcept C146357865 @default.
• W3174236351 hasConcept C151730666 @default.
• W3174236351 hasConcept C2776694085 @default.
• W3174236351 hasConcept C2779338263 @default.
• W3174236351 hasConcept C2780653079 @default.
• W3174236351 hasConcept C2780775027 @default.
• W3174236351 hasConcept C2780790343 @default.
• W3174236351 hasConcept C2908647359 @default.
• W3174236351 hasConcept C509974204 @default.
• W3174236351 hasConcept C71924100 @default.
• W3174236351 hasConcept C86803240 @default.
• W3174236351 hasConcept C87355193 @default.
• W3174236351 hasConcept C99454951 @default.
• W3174236351 hasConceptScore W3174236351C121332964 @default.
• W3174236351 hasConceptScore W3174236351C126322002 @default.
• W3174236351 hasConceptScore W3174236351C141071460 @default.
• W3174236351 hasConceptScore W3174236351C142424586 @default.
• W3174236351 hasConceptScore W3174236351C143998085 @default.
• W3174236351 hasConceptScore W3174236351C146357865 @default.
• W3174236351 hasConceptScore W3174236351C151730666 @default.
• W3174236351 hasConceptScore W3174236351C2776694085 @default.
• W3174236351 hasConceptScore W3174236351C2779338263 @default.
• W3174236351 hasConceptScore W3174236351C2780653079 @default.
• W3174236351 hasConceptScore W3174236351C2780775027 @default.
• W3174236351 hasConceptScore W3174236351C2780790343 @default.
• W3174236351 hasConceptScore W3174236351C2908647359 @default.
• W3174236351 hasConceptScore W3174236351C509974204 @default.
• W3174236351 hasConceptScore W3174236351C71924100 @default.
• W3174236351 hasConceptScore W3174236351C86803240 @default.
• W3174236351 hasConceptScore W3174236351C87355193 @default.
• W3174236351 hasConceptScore W3174236351C99454951 @default.
• W3174236351 hasIssue "S2" @default.
• W3174236351 hasLocation W31742363511 @default.
• W3174236351 hasOpenAccess W3174236351 @default.
• W3174236351 hasPrimaryLocation W31742363511 @default.
• W3174236351 hasRelatedWork W1535958986 @default.
• W3174236351 hasRelatedWork W1987468340 @default.
• W3174236351 hasRelatedWork W2040492280 @default.
• W3174236351 hasRelatedWork W2048191209 @default.
• W3174236351 hasRelatedWork W2376593068 @default.
• W3174236351 hasRelatedWork W2390264150 @default.
• W3174236351 hasRelatedWork W2404042595 @default.
• W3174236351 hasRelatedWork W2416632858 @default.
• W3174236351 hasRelatedWork W2469233091 @default.
• W3174236351 hasRelatedWork W4220939315 @default.
• W3174236351 hasVolume "39" @default.
• W3174236351 isParatext "false" @default.
• W3174236351 isRetracted "false" @default.
• W3174236351 magId "3174236351" @default.
• W3174236351 workType "article" @default.